Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TEVA POWR Grades
- TEVA scores best on the Value dimension, with a Value rank ahead of 97.1% of US stocks.
- TEVA's strongest trending metric is Growth; it's been moving down over the last 179 days.
- TEVA's current lowest rank is in the Momentum metric (where it is better than 17.34% of US stocks).
TEVA Stock Summary
- TEVA has a higher market value than 85.15% of US stocks; more precisely, its current market capitalization is $11,706,196,287.
- TEVA PHARMACEUTICAL INDUSTRIES LTD's stock had its IPO on March 26, 1990, making it an older stock than 86.19% of US equities in our set.
- Over the past twelve months, TEVA has reported earnings growth of -156.13%, putting it ahead of just 10.09% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to TEVA PHARMACEUTICAL INDUSTRIES LTD are BAX, XRAY, XRX, AGFS, and OBLG.
- TEVA's SEC filings can be seen here. And to visit TEVA PHARMACEUTICAL INDUSTRIES LTD's official web site, go to www.tevapharm.com.
TEVA Valuation Summary
- In comparison to the median Healthcare stock, TEVA's EV/EBIT ratio is 367.98% lower, now standing at -27.2.
- Over the past 243 months, TEVA's EV/EBIT ratio has gone down 47.2.
Below are key valuation metrics over time for TEVA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TEVA | 2023-01-30 | 0.8 | 1.3 | -8.8 | -27.2 |
| TEVA | 2023-01-27 | 0.8 | 1.3 | -8.9 | -27.3 |
| TEVA | 2023-01-26 | 0.8 | 1.3 | -8.8 | -27.2 |
| TEVA | 2023-01-25 | 0.7 | 1.3 | -8.8 | -27.2 |
| TEVA | 2023-01-24 | 0.8 | 1.3 | -8.8 | -27.2 |
| TEVA | 2023-01-23 | 0.8 | 1.3 | -8.9 | -27.3 |
TEVA Growth Metrics
- Its 2 year cash and equivalents growth rate is now at 20.57%.
- Its 2 year price growth rate is now at -25.54%.
- Its 3 year net cashflow from operations growth rate is now at 8.66%.
The table below shows TEVA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 15,142 | 1,073 | -1,290 |
| 2022-06-30 | 15,434 | 1,059 | -1,054 |
| 2022-03-31 | 15,558 | 1,154 | -615 |
| 2021-12-31 | 15,878 | 798 | 417 |
| 2021-09-30 | 16,232 | 673 | 726 |
| 2021-06-30 | 16,323 | 451 | -3,915 |
TEVA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TEVA has a Quality Grade of C, ranking ahead of 57.93% of graded US stocks.
- TEVA's asset turnover comes in at 0.33 -- ranking 140th of 682 Pharmaceutical Products stocks.
- LFVN, ONVO, and ANAB are the stocks whose asset turnover ratios are most correlated with TEVA.
The table below shows TEVA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.330 | 0.468 | 0.064 |
| 2021-06-30 | 0.329 | 0.469 | -0.088 |
| 2021-03-31 | 0.319 | 0.463 | -0.097 |
| 2020-12-31 | 0.316 | 0.464 | -0.102 |
| 2020-09-30 | 0.298 | 0.471 | -0.108 |
| 2020-06-30 | 0.293 | 0.462 | 0.018 |
TEVA Stock Price Chart Interactive Chart >
TEVA Price/Volume Stats
| Current price | $10.54 | 52-week high | $11.44 |
| Prev. close | $10.26 | 52-week low | $6.78 |
| Day low | $10.27 | Volume | 9,138,600 |
| Day high | $10.70 | Avg. volume | 10,674,155 |
| 50-day MA | $9.51 | Dividend yield | N/A |
| 200-day MA | $8.88 | Market Cap | 11.71B |
Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.
Latest TEVA News From Around the Web
Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.
Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & MoreUpdates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week. |
Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025When the lights went out on 2022, all three major U.S. stock indexes had delivered their worst returns since 2008. While the Nasdaq losing a third of its value in such a short time frame is undoubtedly brutal for short-term traders, it represents a generational opportunity for patient investors to snag high-quality stocks at a discount. The first surefire bargain that has the potential to double your money by mid-decade is brand-name and generic-drug producer Teva Pharmaceutical Industries (NYSE: TEVA). |
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse GenericCatalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse. |
Dow, Nasdaq Boasting Triple-Digit Midday LeadInvestors seem intent on leaving last week's losses behind, as earnings season heats up. |
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only ProductTeva said Monday it plans to knock off Catalyst's only approved drug and CPRX stock — which has sat atop the IBD 50 for weeks — crashed. |
TEVA Price Returns
| 1-mo | N/A |
| 3-mo | 22.42% |
| 6-mo | -1.40% |
| 1-year | 21.01% |
| 3-year | 1.35% |
| 5-year | -48.76% |
| YTD | 15.57% |
| 2022 | 13.86% |
| 2021 | -16.99% |
| 2020 | -1.53% |
| 2019 | -36.45% |
| 2018 | -18.63% |
Continue Researching TEVA
Want to see what other sources are saying about Teva Pharmaceutical Industries Ltd's financials and stock price? Try the links below:Teva Pharmaceutical Industries Ltd (TEVA) Stock Price | Nasdaq
Teva Pharmaceutical Industries Ltd (TEVA) Stock Quote, History and News - Yahoo Finance
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...